Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 9, Issue 5, 2003, Pages 304-311

  Jacobson, Pamala A ^a   Ng, Juki ^a   Green, Kathleen G E ^a   Rogosheske, John ^b   Brundage, Richard ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cyclosporine pharmacokinetics; Nonlinear mixed effects model; Population pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE; AMLODIPINE; AMPHOTERICIN B; BILIRUBIN; BUSULFAN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 INHIBITOR; DILTIAZEM; FLUCONAZOLE; FOSCARNET; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ITRACONAZOLE; LYMPHOCYTE ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IN VIVO STUDY; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STEADY STATE; T LYMPHOCYTE; VEIN OCCLUSION; WHOLE BODY RADIATION; BIOAVAILABILITY; DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 1542787225     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(03)00076-4     Document Type: Article

References (39)

1. Miller K.B. Schenkein D.P. Comenzo R. et al. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation Ann Hematol. 68 1994 15-20
2. Gondo H. Harde M. Taniguchi S. et al. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease Bone Marrow Transplant. 2 1993 437-441
3. Yee G.C. Self S.G. McGuire T.R. et al. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation N Engl J Med. 319 1988 65-70
4. Parkman R. Cyclosporine: GVHD and beyond N Engl J Med. 319 1988 110-111
5. Przepiorka D. Shapiro S. Schwinghammer T.L. et al. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: Association between low cyclosporine concentration and risk of acute graft-versus-host disease Bone Marrow Transplant. 7 1991 461-465
6. Schmidt H. Ehninger G. Dopfer R. et al. Correlation between low CSA plasma concentration and severity of acute GvHD in bone marrow transplantation Blut. 57 1988 139-142
7. Kennedy M.S. Yee G.C. McGuire T.R. et al. Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients Transplantation 40 1985 249-253
8. Lindholm A. Ringden O. Lonnqvist B. The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients Transplantation 43 1987 680-684
9. Wang C.P. Hartman N.R. Venkataramanan R. et al. Isolation of 10 cyclosporine metabolites from human bile Drug Metab Dispos. 17 1989 992-996
10. Venkataramanan R. Habucky K. Burckart G.J. et al. Clinical pharmacokinetics in organ transplant patients Clin Pharmacokinet. 16 1989 134-161
11. Ptachcinski R.J. Venkataramanan R. Rosenthal J.T. et al. The effect of food on cyclosporine absorption Transplantation 40 1985 174-176
12. Dunn C.J. Wagstaff A.J. Perry C.M. et al. Cyclosporin: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation Drugs 61 2001 1957-2016
13. Legg B. Rowland M. Cyclosporin: Measurement of fraction unbound in plasma J Pharm Pharmacol. 39 1987 599-603
14. Trotter J.F. Drugs that interact with immunosuppressive agents Semin Gastrointest Dis. 9 1998 147-153
15. Zaghloul I. Ptachcinski R.J. Burckart G.J. et al. Blood protein binding of cyclosporine in transplant patients J Clin Pharmacol. 27 1987 240-242
16. Ptachcinski R.J. Venkataramanan R. Rosenthal J.T. et al. Cyclosporine kinetics in renal transplantation Clin Pharmacol Ther. 38 1985 296-300
17. Ptachcinski R.J. Venkataramanan R. Burckart G.J. Clinical pharmacokinetics of cyclosporin Clin Pharmacokinet. 11 1986 107-132
18. Parke J. Charles B.G. NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation Ther Drug Monit. 20 1998 284-293
19. Carruthers S.G. Freeman D.J. Koeglar J.C. et al. Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay Clin Chem. 29 1983 180-183
20. Sawchuk R.J. Cartier L.L. Liquid-chromatographic determination of cyclosporin A in blood and plasma Clin Chem. 27 1981 1368-1371
21. Lensmeyer G.L. Fields B.L. Improved liquid-chromatographic determination of cyclosporine, with concomitant detection of a cell-bound metabolite Clin Chem. 31 1985 196-201
22. Thomas E.D. Storb R. Clife R.A. et al. Bone-marrow transplantation (second of two parts) N Engl J Med. 292 1975 895-902
23. Weisdorf D.J. Shover D.C. Haake R. et al. Acute upper gastrointestinal graft-versus-host disease: Clinical significance and response to immunosuppressive therapy Blood 76 1990 624-629
24. Glucksberg H. Storb R. Fefer A. et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors Transplantation 18 1974 295-304
25. Przepiorka D. Weisdorf D. Martin P. et al. 1994 Consensus Conference on Acute GVHD Grading Bone Marrow Transplant. 15 1995 825-828
26. Rowlings P.A. Przepiorka D. Klein J.P. et al. IBMTR Severity Index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade Br J Haematol. 97 1997 855-864
27. Beal L. SL. NONMEM User Guide 1992 NONMEM Project Group, UCSFSan Francisco, CA
28. Schwinghammer T.L. Przepiorka D. Venkataramanan R. et al. The kinetics of cyclosporine and its metabolites in bone marrow transplant patients Br J Clin Pharmacol. 32 1991 323-328
29. Parquet N. Reigneau O. Humbert H. et al. New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients Bone Marrow Transplant. 25 2000 965-968
30. Yee G.C. Kennedy M.S. Storb R. et al. Effect of hepatic dysfunction on oral cyclosporin pharmacokinetics in marrow transplant patients Blood 64 1984 1277-1279
31. Kahan B.D. Kramer W.G. Wideman C. et al. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay Transplantation 41 1986 459-464
32. Moyer T.P. Johnson P. Faynor S.M. et al. Cyclosporine: A review of drug monitoring problems and presentation of a simple, accurate liquid chromatographic procedure that solves these problems Clin Biochem. 19 1986 83-89
33. Donatsch P. Abisch E. Homberger M. et al. A radioimmunoassay to measure cyclosporin A in plasma and serum samples J Immunoassay. 2 1981 19-32
34. Schultz K.R. Nevill T.J. Joze C.L. et al. The pharmacokinetics of oral cyclosporin A (Neoral) during the first month after bone marrow transplantation Transplant Proc. 30 1998 1668-1670
35. Atkinson K. Biggs J.C. Britton K. et al. Oral administration of cyclosporin A for recipients of allogeneic marrow transplants: Implications of clinical gut dysfunction Br J Haematol. 56 1984 223-231
36. Yee G.C. McGuire T.R. Gmur D.J. et al. Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation. Influence of age, obesity, and hematocrit Transplantation 46 1988 399-402
37. McLachlan A.J. Tett S.E. Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach Ther Drug Monit. 20 1998 390-395
38. Yee G.C. McGuire T.R. Pharmacokinetic drug interactions with cyclosporin (Part I) Clin Pharmacokinet. 19 1990 319-332
39. Yee G.C. McGuire T.R. Pharmacokinetic drug interactions with cyclosporin (Part II) Clin Pharmacokinet. 19 1990 400-415